Durvalumab Approved for Muscle-Invasive Bladder Cancer in UK – Promising Results
- The National Institute for Health and Care Excellence (NICE), in the United Kingdom, has issued a final positive recommendation for the use of durvalumab, in combination with gemcitabine...
- The decision is based on results from the Phase 3 NIAGARA trial, which included 1,063 patients with MIBC.
- MIBC is characterized by tumor infiltration into the muscle layer of the bladder, without distant metastasis.
The National Institute for Health and Care Excellence (NICE), in the United Kingdom, has issued a final positive recommendation for the use of durvalumab, in combination with gemcitabine and cisplatin in the pre-operative period and as monotherapy following surgery, for adults with resectable muscle-invasive bladder cancer (MIBC). This marks the first time a perioperative immune-oncology treatment has been approved for this patient population within the UK’s National Health Service.
The decision is based on results from the Phase 3 NIAGARA trial, which included 1,063 patients with MIBC. The trial compared outcomes between patients receiving durvalumab alongside neoadjuvant chemotherapy (gemcitabine and cisplatin), followed by durvalumab monotherapy, versus those receiving chemotherapy alone before radical cystectomy. The study demonstrated a 32% reduction in the risk of disease progression in the durvalumab arm compared to standard treatment.
MIBC is characterized by tumor infiltration into the muscle layer of the bladder, without distant metastasis. In England, saw 18,060 new cases of bladder cancer diagnosed. The disease predominantly affects individuals in their sixth and seventh decades of life, with a higher incidence among men. Approximately 630 patients per year in the UK are estimated to be eligible for this new therapy.
Currently, the standard treatment for MIBC involves cisplatin-based chemotherapy followed by radical cystectomy. However, approximately half of patients with muscle-invasive disease experience recurrence or progression within five years. Durvalumab, a human anti-PD-L1 monoclonal antibody, works by blocking the interaction between the PD-L1 protein and its receptors, PD-1 and CD80, thereby enhancing the immune system’s ability to recognize and destroy tumor cells.
In the NIAGARA trial, at , patients treated with the durvalumab regimen had a two-year overall survival rate of 82.2% compared to 75.2% in the control group. Event-free survival at two years was 67.8% in the durvalumab arm versus 59.8% in the comparator arm. Adverse events of grade 3 or 4 occurred in similar proportions between the groups (69.4% vs. 67.5%).
“This positive NICE recommendation represents an important step forward for people living with one of the most aggressive forms of bladder cancer,” stated Tom Keith-Roach, President of AstraZeneca UK.
NICE concluded that, despite uncertainties in long-term models, the incremental cost-effectiveness ratio was within an acceptable range for the National Health Service. Following the final publication of the guidance, the treatment is expected to be implemented within the UK’s public healthcare system within 90 days.
The implications of this approval extend beyond the UK. Globally, bladder cancer remains a significant health concern. According to estimates from the National Cancer Institute (INCA) in Brazil, approximately 11,300 new cases of bladder cancer are expected annually between and , with around 7,870 in men and 3,500 in women. It is the sixth most common cancer diagnosed in Brazilian men, excluding non-melanoma skin cancers. Data from the Brazilian agency Agência Brasil indicate that between and , the disease was responsible for over 19,000 deaths in the country, highlighting its substantial public health impact.
The approval of durvalumab represents a shift in the treatment paradigm for MIBC, moving towards a perioperative immunotherapy approach. This strategy aims to reduce the risk of recurrence and improve long-term survival by harnessing the power of the patient’s own immune system to fight the cancer both before and after surgical removal of the bladder. The NIAGARA trial results, published in The New England Journal of Medicine, provide strong evidence supporting the efficacy and safety of this approach.
Experts have hailed the findings as a “major breakthrough” and a “game changer” in bladder cancer treatment. Prof. James Catto from the University of Sheffield described the results as offering “hope to thousands of patients” facing a devastating diagnosis. The University of Sheffield and Barts Cancer Institute at Queen Mary University of London jointly led the trial.
While this new treatment offers significant promise, it’s important to remember that it is not a cure for all patients. Ongoing monitoring and follow-up care will remain crucial for individuals undergoing this therapy. Further research is also needed to identify biomarkers that can predict which patients are most likely to benefit from durvalumab and to optimize the treatment regimen for maximum effectiveness.